Total raised
$37.7M
Last: PIPE 2016-10
Stage
Acquired
Founded
2004
Headcount
1-10
HQ
Jerusalem
Sector
Health Tech & Life Sciences
About
Anchiano Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat cancer-related diseases. Its most advanced product candidate, BC-819, is under development as a treatment for non-muscle-invasive bladder cancer. Anchiano also develops a second-generation drug, BC-821, for the systemic treatment of advanced malignant neoplasms. Preclinical studies of BC-821 have showed significant efficacy in different cancer animal models, such as metastatic lung cancer and metastatic liver cancer. AnchianoTherapeutics is a direct subsidiary of Clal Biotechnology Industries Ltd.
Funding history · 2 rounds · $37.7M total
2016-10
PIPE
$4.7M
2012-11
PIPE
$4.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentMedical DevicesMedical Treatment & Therapeutics
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
cancerbiotechnologybiopharmaceuticalcell-therapybiopsytargeted-therapypharma-companies